Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Care Patients), By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care), And By Geography - Forecasts From 2023 To 2028

The continuous glucose monitoring market is expected to grow at a CAGR of 19.16%, from a valuation of US$4.896 billion in 2021 to US$16.698 billion by 2028.

Continuous glucose monitoring refers to a system used for tracking a person’s blood glucose level throughout the day. It uses a tiny sensor that, when inserted under the skin, does the glucose test and conveys the recorded data through a wireless transmitter. The demand for continuous glucose monitoring is expected to show a significant surge due to the growing prevalence of diabetes throughout the world.

Market Drivers:

Growing prevalence of diabetes

Continuous glucose monitoring enables diabetic patients to keep their sugar level under control and it provides necessary data to the doctors that enable them to decide the type of treatment that needs to be given to the patient. Over the years diabetes prevalence has shown a significant increase owing to the lack of physically active, insulin resistance, unhealthy lifestyle, and gene factors. For instance, according to the data issued by International Diabetes Federation in its Atlas 2021 report, the total number of people aged 20 to 79 years who had diabetes stood at 537 million which showed an increase of 15.9% in comparison to 463 million reported in 2019. Furthermore, as per the same source, the number is expected to increase to 643 million by 2030 and 783 million by 2045. Such an increase in the number of people having diabetes globally will create a surge in the demand for continuous glucose monitoring devices for keeping a closer watch on the sugar level of the people, which will propel the overall market growth in the future.

Governments all over the world have established programs and provided subsidies to train and distribute continuous glucose monitoring devices to diabetes patients and healthcare providers. For instance, the Department of Health and Aged Care, Australia announced in February 2020 that Australians with type 1 diabetes will soon be able to use the FreeStyle Libre flash glucose monitoring equipment for free. Australians would ordinarily spend $92.50 every two weeks for the FreeStyle Libre flash glucose monitoring kit if the government did not subsidize it. Through the National Diabetes Services Scheme (NDSS) Initiative, the Australian Government has recently expanded access to subsidized Continuous Glucose Monitoring (CGM) for Australians with type 1 diabetes.

Recent Developments:

The rising investments by companies operating in this segment to commercialize their products are also expected to push the demand for such devices. For instance, in September 2022, Transdermal Diagnostics received investments of £1.1 million from Innovate UK to commercialize the production of the company’s wearable continuous glucose monitor. Also, in November 2021, US-based medical device start-up Biolinq Inc. raised investments of US$100 million which will be used for the production of continuous glucose monitor devices containing needle-free biosensors for tracking the sugar level of type-2 diabetes patients.

Furthermore, product launches and innovations are also acting as additional factors driving the continuous glucose monitoring market growth. For instance, in May 2022, DexCom launched its new CGM device “Dexcom ONE” in the United Kingdom, which can continuously monitor and send real-time values of glucose levels to a compatible smart device through the Dexcom ONE app.

Innovations have made equipment smaller, more convenient, and more reliable; networked, innovative, and automated monitoring is on the horizon. For instance, The FDA approved Senseonics' long-lasting continuous glucose monitor. The FDA-approved CGM from Senseonics includes a sensor that lasts six months, a first for any CGM. Other rival systems from Medtronic and Dexcom last three to ten days.

Based on application, it is anticipated that the diabetes patients’ segment would continue dominating the continuous glucose monitoring market due to factors such as the rising rate of diabetes, growing demand for diabetes monitoring devices with favorable reimbursement policies, and the introduction of cutting-edge technology. This growth is being driven on account of the faster rising prevalence of diabetes in low- and middle-income nations than in high-income countries. Diabetes is a leading cause of blindness, kidney failure, heart attacks, stroke, and amputation of lower limbs.

Regional Insights:

By geography, the continuous glucose monitoring market has been segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific regions. The demand for continuous glucose monitoring (CGM) solutions will rise substantially due to an increase in the geriatric population and surging diabetes prevalence in North America. This region has been witnessing multiple investment opportunities by major companies for the development of novel and advanced glucose monitoring solutions. The United States, for example, has witnessed a growing surge in its spending mainly for the development of advanced glucose monitoring solutions. A significant sum by various companies is being spent on the development of high-quality, innovative, and advanced glucose monitoring solutions and devices. For instance, in October 2021, one of the most promising players in the market, GraphWear raised US$20.5 million in its latest series B funding mainly which was focused on the development of an advanced needle-free continuous glucose monitoring platform.

Continuous Glucose Monitoring (CGM) Market Scope:

 

Report Metric	Details
Market Size Value in 2021	US$4.896 billion
Market Size Value in 2028	US$16.698 billion
Growth Rate	CAGR of 19.16% from 2021 to 2028
Base Year	2021
Forecast Period	2023–2028
Forecast Unit (Value)	USD Billion
Segments Covered	Application, End-User Industry, And Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Dexcom Inc, Abbott Laboratories, Medtronics Pvt. Ltd, GlySens, Medtrum Technologies Inc., Tandem Diabetes Care, Sensonics, A. Menarini Diagnostics s.r.l, Roche Diagnostics, Ypsomed AG
Customization Scope	Free report customization with purchase

 

Market Segmentation:

• By Application
  • Diabetes Patients
  • Critical Care Patients
• By End-User Industry
  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • The Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Indonesia
    • Thailand
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

 

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Sources

2.3. Research Design

 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

 

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Care Patients

 

6. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

 

7. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY GEOGRAPHY 

7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. UK

7.4.2. France

7.4.3. Germany 

7.4.4. Spain

7.4.5. Others 

7.5. Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Israel

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. South Korea

7.6.5. Taiwan

7.6.6. Indonesia

7.6.7. Thailand

7.6.8. Others

 

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

 

9. COMPANY PROFILES

9.1. Dexcom Inc

9.2. Abbott Laboratories

9.3. Medtronics Pvt. Ltd

9.4. GlySens

9.5. Medtrum Technologies Inc.

9.6. Tandem Diabetes Care

9.7. Sensonics 

9.8. A. Menarini Diagnostics s.r.l

9.9. Roche Diagnostics

9.10. Ypsomed AG

Dexcom Inc

Abbott Laboratories

Medtronics Pvt. Ltd

GlySens

Medtrum Technologies Inc.

Tandem Diabetes Care

Sensonics

A. Menarini Diagnostics s.r.l

Roche Diagnostics

Ypsomed AG